Can moderate elevations of parathyroid hormone acutely increase risk for ischemic cardiac arrhythmias?

Medical Hypotheses

Volumn 72, Issue 5, 2009, Pages 581-583

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR; ENDOTHELIN A RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEART RECEPTOR; PARATHYROID HORMONE; PHOSPHOLIPASE C; VITAMIN D;

ARTICLE; CALCIUM INTAKE; CARDIOVASCULAR RISK; ENZYME ACTIVATION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE DETERMINATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; WEIGHT GAIN;

ANIMALIA;

EID: 60849091024     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.12.023     Document Type: Article

References (49)

1. Sambrook P.N., Chen J.S., March L.M., Cameron I.D., Cumming R.G., Lord S.R., et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab 89 (2004) 5477-5481
2. Kamycheva E., Sundsfjord J., and Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso study. Eur J Cardiovasc Prev Rehab 11 (2004) 69-74
3. Chiu K.C., Chuang L.M., Lee N.P., Ryu J.M., McGullam J.L., Tsai G.P., et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism JID - 0375267 49 (2000) 1501-1505
4. McCarty M.F. Vitamin D, parathyroid hormone, and insulin sensitivity. Am J Clin Nutr 80 (2004) 1451-1452
5. McCarty M.F., and Thomas C.A. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 61 (2003) 535-542
6. McCarty M.F. A moderately low phosphate intake may provide health benefits analogous to those conferred by UV light - a further advantage of vegan diets. Med Hypotheses 61 (2003) 543-560
7. Morfis L., Smerdely P., and Howes L.G. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 15 (1997) 1271-1276
8. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension JID - 7906255 30 (1997) 150-156
9. Fliser D., Franek E., Fode P., Stefanski A., Schmitt C.P., Lyons M., et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant JID - 8706402 12 (1997) 933-938
10. Jorde R., Sundsfjord J., Haug E., and Bonaa K.H. Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension 35 (2000) 1154-1159
11. Pfeifer M., Begerow B., Minne H.W., Nachtigall D., and Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86 (2001) 1633-1637
12. Bauwens F.R., Duprez D.A., De Buyzere M.L., De Backer T.L., Kaufman J.M., Van Hoecke J., et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 68 (1991) 925-929
13. Saleh F.N., Schirmer H., Sundsfjord J., and Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24 (2003) 2054-2060
14. Andersson P., Rydberg E., and Willenheimer R. Primary hyperparathyroidism and heart disease - a review. Eur Heart J 25 (2004) 1776-1787
15. McCarty MF. Nutritional modulation of parathyroid hormone secretion may influence risk for left ventricular hypertrophy. Med Hypotheses 2005;64:1015-21.
16. McCarty MF. Secondary hyperparathyroidism promotes the acute phase response - a rationale for supplemental vitamin D in prevention of vascular events in the elderly. Med Hypotheses 2005;64:1022-6.
17. Schluter K.D., and Piper H.M. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 263 (1992) H1739-H1746
18. Schluter K.D., Weber M., and Piper H.M. Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity. Biochem J 310 Pt 2 (1995) 439-444
19. Schluter K.D., and Piper H.M. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37 (1998) 34-41
20. Lamers J.M., De Jonge H.W., Panagia V., and van Heugten H.A. Receptor-mediated signalling pathways acting through hydrolysis of membrane phospholipids in cardiomyocytes. Cardioscience 4 (1993) 121-131
21. Eskildsen-Helmond Y.E., Bezstarosti K., Dekkers D.H., van Heugten H.A., and Lamers J.M. Cross-talk between receptor-mediated phospholipase C-beta and D via protein kinase C as intracellular signal possibly leading to hypertrophy in serum-free cultured cardiomyocytes. J Mol Cell Cardiol 29 (1997) 2545-2559
22. Long C.S., Kariya K., Karns L., and Simpson P.C. Sympathetic activity: modulator of myocardial hypertrophy. J Cardiovasc Pharmacol 17 Suppl. 2 (1991) S20-S24
23. Knowlton K.U., Michel M.C., Itani M., Shubeita H.E., Ishihara K., Brown J.H., et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 268 (1993) 15374-15380
24. Kelm M., Schafer S., Mingers S., Heydthausen M., Vogt M., Motz W., et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 14 (1996) 1357-1364
25. Sadoshima J., Xu Y., Slayter H.S., and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 (1993) 977-984
26. White M. Cardioprotective effect of angiotensin II receptor antagonists. Can J Cardiol 15 Suppl. F (1999) 10F-14F
27. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 265 (1990) 20555-20562
28. Ehmke H., Faulhaber J., Munter K., Kirchengast M., and Wiesner R.J. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 33 (1999) 954-960
29. Hua L., Li C., Xia D., Qu P., Li Z., Zhang W., et al. Relationship between hypertensive left ventricular hypertrophy and levels of endothelin and nitric oxide. Hypertens Res 23 (2000) 377-380
30. Wolf S.C., Gaschler F., Brehm S., Klaussner M., Amann K., Risler T., et al. Endothelin-receptor antagonists in uremic cardiomyopathy. J Cardiovasc Pharmacol 36 (2000) S348-S350
31. Ramirez G., Brueggemeyer C.D., and Newton J.L. Cardiac arrhythmias on hemodialysis in chronic renal failure patients. Nephron 36 (1984) 212-218
32. Soldati L., Adamo D., Manunta P., Stella P., Ciurlino D., Spotti D., et al. Erythrocyte calcium influx is related to severity of ventricular arrhythmias in uraemic patients. Nephrol Dial Transplant 16 (2001) 85-90
33. Billman G.E. The effect of adrenergic receptor antagonists on cocaine-induced ventricular fibrillation: alpha but not beta adrenergic receptor antagonists prevent malignant arrhythmias independent of heart rate. J Pharmacol Exp Ther 269 (1994) 409-416
34. Tolg R., Kurz T., Ungerer M., Schreieck J., Gorge B., and Richardt G. Influence of alpha- and beta-adrenoceptor antagonists on ventricular fibrillation in ischemic rat hearts. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 62-68
35. Corr P.B., Heathers G.P., and Yamada K.A. Mechanisms contributing to the arrhythmogenic influences of alpha 1-adrenergic stimulation in the ischemic heart. Am J Med 87 (1989) 19S-25S
36. Kurz T., Yamada K.A., DaTorre S.D., and Corr P.B. Alpha 1-adrenergic system and arrhythmias in ischaemic heart disease. Eur Heart J 12 Suppl. F (1991) 88-98
37. Billman G.E. Effect of alpha 1-adrenergic receptor antagonists on susceptibility to malignant arrhythmias: protection from ventricular fibrillation. J Cardiovasc Pharmacol 24 (1994) 394-402
38. Yahiro E., Ideishi M., Wang L.X., Urata H., Kumagai K., Arakawa K., et al. Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor. Cardiology 99 (2003) 61-67
39. Gavras I., and Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens 13 (2000) 512-517
40. Hiura N., Wakatsuki T., Yamamoto T., Nishikado A., Oki T., and Ito S. Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 38 (2001) 729-736
41. de Boer R.A., van Geel P.P., Pinto Y.M., Suurmeijer A.J., Crijns H.J., van Gilst W.H., et al. Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. J Cardiovasc Pharmacol 39 (2002) 610-619
42. Garjani A., Wainwright C.L., Zeitlin I.J., Wilson C., and Slee S.J. Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 25 (1995) 634-642
43. Merkely B., Szabo T., Geller L., Kiss O., Horkay F., Raschack M., et al. The selective endothelin-A-receptor antagonist LU 135.252 inhibits the direct arrhythmogenic action of endothelin-1. J Cardiovasc Pharmacol 36 (2000) S314-S316
44. Kiss O., Geller L., Merkely B., Szabo T., Raschack M., Seres L., et al. Endothelin-A-receptor antagonist LU 135.252 inhibits the formation of ventricular arrhythmias caused by intrapericardial infusion of endothelin-1. J Cardiovasc Pharmacol 36 (2000) S317-S319
45. Duru F., Barton M., Luscher T.F., and Candinas R. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?. Cardiovasc Res 49 (2001) 272-280
46. Lin L., and Yuan W.J. Involvement of endothelin-1 in acute ischaemic arrhythmias in cats and rats. Clin Sci (Lond) 103 Suppl. 48 (2002) 228S-232S
47. Woodcock E.A., Arthur J.F., Harrison S.N., Gao X.M., and Du X.J. Reperfusion-induced Ins(1,4,5)P(3) generation and arrhythmogenesis require activation of the Na(+)/Ca(2+) exchanger. J Mol Cell Cardiol 33 (2001) 1861-1869
48. Mackenzie L., Bootman M.D., Laine M., Berridge M.J., Thuring J., Holmes A., et al. The role of inositol 1,4,5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol 541 (2002) 395-409
49. Woodcock E.A., Arthur J.F., and Matkovich S.J. Inositol 1,4,5-trisphosphate and reperfusion arrhythmias. Clin Exp Pharmacol Physiol 27 (2000) 734-737